热门资讯> 正文
Gossamer Bio宣布进行高达2.5亿美元的私募
2026-08-21 21:19
- Gossamer Bio (GOSS) announced on Friday a private placement expected to provide up to approximately $250M in gross proceeds.
- The financing includes $150M of committed capital, with approximately $25M funded at the initial closing and another $125M upon FDA acceptance of the seralutinib NDA in pulmonary arterial hypertension, or PAН.
- The offering is expected to close on or about August 24, 2026.
- FDA approval warrants could provide up to an additional $100M in gross proceeds at an exercise price of $0.187 per share.
- The financing includes participation from new and existing institutional investors, including EcoR1 Capital, 683 Capital Partners, RA Capital Management, Coastlands Capital, Samsara BioCapital, and Rock Springs Capital.
- Proceeds will support seralutinib through potential FDA approval in PAH.
More on Gossamer Bio
- Gossamer Bio, Inc. (GOSS) Discusses Reacquisition of Seralutinib Rights, Regulatory Progress and Capital Structure Updates Transcript
- Seeking Alpha’s Quant Rating on Gossamer Bio
- Historical earnings data for Gossamer Bio
- Financial information for Gossamer Bio
推荐文章
美股前瞻 | 英伟达强劲指引"炸场"！绩后大涨6%，带动存储、光通信齐冲高；美国酝酿半导体新关税；Modema将发行巨额可转债
70%增长不是天花板！英伟达首次抛出远期指引，AI Factory下一波红利流向哪里？
全文|英伟达Q2业绩会实录：内存涨价超出预期 不怕合作伙伴竞争
财报和电话会两重天 英伟达投资者和股价跟着AI展望一起坐过山车
Meta与美国多州就社交媒体危害案达成和解 最高将支付约180亿美元
迪克体育用品股价暴跌，暴露出陷入困境的耐克面临一大核心难题
杰克逊霍尔年会前夕：美元、债市高度紧绷，贝森特市场干预给沃什施加巨大压力
Anthropic或将向投资者披露，潜在市场收入规模超30万亿美元
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
